Quote:

---

BP has zero interest in cytodyn other than for leronlimab, there is nothing else to the company to partner with. I think they want to pick up this and run with it 100%. If this possibility was not in the range that surpasses the 50% royalty partnership deal, Nader and the board would not take it seriously enough to pause this.

---

The only problem with that is that any BO offer would be worse than the partnership deal. Let's say the offer is $5 billion. Less than one year's sales in monotherapy. $10 billion, less than one years sales in NASH. $15 billion, less than one years sales in cancer.

BP will never offer us what our drug is worth at any stage because once we hit revenue we don't need them and as approvals are added the cost would be prohibitive. IF NP is even considering a paltry BO offer at this stage I would be sadly disappointed.